Obalon Therapeutics, Inc. (OBLN) EPS Estimated At $-0.48

February 21, 2018 - By Dolores Ford

 Obalon Therapeutics, Inc. (OBLN) EPS Estimated At $ 0.48

Analysts expect Obalon Therapeutics, Inc. (NASDAQ:OBLN) to report $-0.48 EPS on February, 22.They anticipate $0.03 EPS change or 5.88 % from last quarter’s $-0.51 EPS. After having $-0.55 EPS previously, Obalon Therapeutics, Inc.’s analysts see -12.73 % EPS growth. The stock increased 5.22% or $0.21 during the last trading session, reaching $4.23. About 135,776 shares traded. Obalon Therapeutics, Inc. (NASDAQ:OBLN) has 0.00% since February 21, 2017 and is . It has underperformed by 16.70% the S&P500.

Obalon Therapeutics, Inc. (NASDAQ:OBLN) Ratings Coverage

Among 2 analysts covering Obalon Therapeutics (NASDAQ:OBLN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Obalon Therapeutics had 2 analyst reports since October 31, 2016 according to SRatingsIntel. As per Monday, October 31, the company rating was initiated by Stifel Nicolaus. The firm earned “Buy” rating on Monday, October 31 by UBS.

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The company has market cap of $73.78 million. It offers the Obalon balloon system designed to provide weight loss in obese patients. It currently has negative earnings.

More notable recent Obalon Therapeutics, Inc. (NASDAQ:OBLN) news were published by: Globenewswire.com which released: “Obalon Announces Termination of Public Offering of Common Stock” on January 23, 2018, also Businesswire.com with their article: “EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action …” published on February 15, 2018, Marketwatch.com published: “Obalon Therapeutics Inc.” on October 06, 2016. More interesting news about Obalon Therapeutics, Inc. (NASDAQ:OBLN) were released by: Globenewswire.com and their article: “Obalon Therapeutics, Inc. to Ring The Nasdaq Stock Market Closing Bell” published on January 19, 2017 as well as Businesswire.com‘s news article titled: “Bragar Eagel & Squire, PC is Investigating Obalon Therapeutics, Inc. (OBLN) on …” with publication date: January 23, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.